ApoB: The Cholesterol Number Standard Panels Miss

Cholesterol numbers alone rarely tell the real story. Particle count does. Two people can have identical LDL cholesterol and very different cardiovascular risk, because LDL cholesterol measures how much cholesterol is riding inside particles — not how many particles are actually circulating and depositing into artery walls. That distinction, more than any other single idea in preventive cardiology, is why some people with “normal” cholesterol still have a heart attack in their fifties.

ApoB: the number that counts the particles

Every LDL particle, along with VLDL and Lp(a), carries exactly one molecule of a protein called apolipoprotein B. Measuring ApoB is effectively counting the total number of atherogenic particles in the blood — the actual vehicles capable of lodging in an artery wall and triggering plaque formation. Two people can have the same LDL cholesterol level with very different ApoB counts, because one of them is carrying the same amount of cholesterol in fewer, larger particles and the other in more numerous, smaller ones. The second pattern is more dangerous, and standard lipid panels miss it entirely.

This is why a growing number of preventive cardiologists treat ApoB, not LDL-C, as the primary target for risk assessment and treatment decisions.

The engineer who ran the marathon and still needed a stent

A man in his early fifties had run three marathons, ate carefully, had never smoked, and had an LDL cholesterol that his previous physician called “borderline acceptable.” He assumed his fitness protected him. An ApoB test told a different story: his particle count was high, driven by a genetic pattern of small, dense LDL that his standard panel had never flagged. A coronary calcium score confirmed measurable plaque already present.

He wasn’t failing at prevention. He was being measured with the wrong tool. Once treated to an ApoB-based target rather than an LDL-C-based one, his particle burden dropped substantially, and repeat imaging over the following years showed no further progression.

Why plaque is a lifetime ledger, not a single test

Atherosclerosis accumulates the way debt accumulates — every year of elevated ApoB adds to a running total that mostly does not reverse. This is why the earlier a person brings ApoB down, the smaller their lifetime plaque burden becomes, and why waiting until symptoms appear means treating a problem that has already been building for decades. The chart above illustrates the concept: total arterial burden tracks cumulative exposure, not a single snapshot in time.

What to actually ask for

• ApoB, not just standard LDL-C — a single, inexpensive addition to a routine lipid panel that most labs already offer.
• Lp(a), checked once — a largely genetic, independent risk factor that doesn’t change much with lifestyle but changes how aggressively other risk factors should be treated.
• Coronary artery calcium (CAC) score — a low-radiation CT scan that directly visualizes existing plaque, useful for people with intermediate risk or a strong family history.
• Treating to a target, not a range — for anyone with elevated ApoB or known plaque, evidence supports treating aggressively rather than settling for “borderline normal.”

Why this matters

A normal LDL cholesterol is reassuring, but it is not the same as a normal cardiovascular risk. If there is a strong family history of early heart disease, or if standard numbers have never quite added up against how carefully someone lives, ApoB and a coronary calcium score close that gap. Ask your physician whether these are appropriate for you at your next visit.

Adapted from Built to Last: The Longevity Blueprint by Charan Shikh, MD.